These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 27622011)

  • 21. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of Real-World Patients with High-Risk
    Quaglino P; Ascierto PA; Consoli F; Queirolo P; Spagnolo F; Morelli MF; Berardi R; Chiarion-Sileni V; Tucci M; Troiani T; Melotti B; Rossi E; Mandala M; Rinaldi G; Marcon IG; Pizzuti M; Del Vecchio M
    Cancer Manag Res; 2023; 15():1271-1281. PubMed ID: 38027240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
    Moschetta M; Mak G; Hauser J; Davies C; Uccello M; Arkenau HT
    Exp Hematol Oncol; 2017; 6():1. PubMed ID: 28078189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma.
    Wang W; Smith JL; Carlino MS; Burmeister B; Pinkham MB; Fogarty GB; Christie DRH; Estall V; Shackleton M; Clements A; Wolfe R; Thao LTP; Paton EJ; Steel V; Williams NC
    Clin Transl Radiat Oncol; 2021 Sep; 30():95-99. PubMed ID: 34458597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
    Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU
    Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
    Muto Y; Ng W; Namikawa K; Takahashi A; Tsutsumida A; Nishida M; Yamazaki N
    Melanoma Res; 2018 Apr; 28(2):151-154. PubMed ID: 29356791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
    Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.
    Awad MM; Sullivan RJ
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):25-33. PubMed ID: 25473943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Onset of vitiligo following targeted therapy for BRAF
    Brugnara S; Sicher M; Bonandini EM; Barbareschi M; Girardelli CR; Caffo O
    Drugs Context; 2019; 8():212582. PubMed ID: 32158480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.
    Rossi E; Maiorano BA; Pagliara MM; Sammarco MG; Dosa T; Martini M; Rindi G; Bria E; Blasi MA; Tortora G; Schinzari G
    Front Oncol; 2019; 9():232. PubMed ID: 31024839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
    BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis.
    Gullapalli K; Mosalem O; Varghese MT; Watat K; Hrinczenko B
    Cureus; 2021 Jul; 13(7):e16431. PubMed ID: 34466299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.